Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Mohammad R. Aghasadeghi 1 Article
Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis
Seyed Davar Siadat, Farzam Vaziri, Mamak Eftekhary, Maryam Karbasian, Arfa Moshiri, Mohammad R. Aghasadeghi, Mehdi S. Ardestani, Meghdad Abdollahpour Alitappeh, Amin Arsang, Abolfazl Fateh, Shahin Najar Peerayeh, Ahmad R. Bahrmand
Osong Public Health Res Perspect. 2015;6(1):9-13.   Published online February 28, 2015
DOI: https://doi.org/10.1016/j.phrp.2014.10.012
  • 2,190 View
  • 20 Download
  • 4 Citations
AbstractAbstract PDF
Objectives
Development of an efficacious vaccine against brucellosis has been a challenge for scientists for many years. At present, there is no licensed vaccine against human brucellosis. To overcome this problem, currently, antigenic determinants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered as potential candidates to develop subunit vaccines.
Methods
In this study, Brucella abortus LPS was used for conjugation to Neisseria meningitidis serogroup B outer membrane vesicle (OMV) as carrier protein using carbodiimide and adipic acid–mediated coupling and linking, respectively. Groups of eight BALB/c mice were injected subcutaneously with 10 μg LPS alone, combined LPS + OMV and conjugated LPS–OMV on 0 days, 14 days, 28 days and 42 days. Anti-LPS IgG was measured in serum.
Results
The yield of LPS to OMV in LPS–OMV conjugate was 46.55%, on the basis of carbohydrate content. The ratio for LPS to OMV was 4.07. The LPS–OMV conjugate was the most immunogenic compound that stimulated following the first injection with increased IgG titer of ∼5-fold and ∼1.3-fold higher than that produced against LPS and LPS in noncovalent complex to OMV (LPS + OMV), respectively. The highest anti-LPS IgG titer was detected 2 weeks after the third injection (Day 42) of LPS–OMV conjugate. The conjugated compound elicited higher titers of IgG than LPS + OMV, that showed a 100–120-fold rise of anti-LPS IgG in mice.
Conclusion
These results indicate that our conjugated LPS–OMV can be used as a brucellosis vaccine, but further investigation is required.

Citations

Citations to this article as recorded by  
  • Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
    Qiong Long, Peng Zheng, Xiao Zheng, Weiran Li, Liangqun Hua, Zhongqian Yang, Weiwei Huang, Yanbing Ma
    Advanced Drug Delivery Reviews.2022; 186: 114321.     CrossRef
  • Outer membrane vesicle vaccines
    Francesca Micoli, Calman A. MacLennan
    Seminars in Immunology.2020; 50: 101433.     CrossRef
  • Designing an immunosensor for detection of Brucella abortus based on coloured silica nanoparticles
    Arash Shams, Bahareh Rahimian Zarif, Mojtaba Salouti, Reza Shapouri, Sako Mirzaii
    Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2562.     CrossRef
  • Bioengineering bacterial outer membrane vesicles as vaccine platform
    Matthias J.H. Gerritzen, Dirk E. Martens, René H. Wijffels, Leo van der Pol, Michiel Stork
    Biotechnology Advances.2017; 35(5): 565.     CrossRef

PHRP : Osong Public Health and Research Perspectives